Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

GlaxoSmithKline files application in Japan for ofatumumab

April 27, 2012

New Roche oncolytic targets chondroitin sulfate proteoglycan 4

April 25, 2012

Advaxis describes two new cancer immunotherapies

April 20, 2012

Melanoma trial of SCIB-1 clear to advance to phase II

April 18, 2012

Morphotek evaluates MORAb-004 in new phase II trial

April 18, 2012

Promising first clinical results reported on Affimed TandAb

April 13, 2012

Biovest to file marketing application in Canada

April 11, 2012

First-in-class cancer immunotherapy well tolerated in phase I trial

April 10, 2012

Roche reports topline data from phase III EMILIA trial

April 2, 2012

New encapsulated stem cell therapy induces cell death in gliomas

March 29, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...